Several oral agents have been proven active in the treatment of certain subtypes of non-Hodgkin lymphomas, including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), follicular lymphoma
Read More >
In a study funded in part by the Lymphoma Research Foundation, researchers find the loss of specific protein amplification and transcriptional reprogramming contribute to resistance
Read More >
Rituximab (Rituxan) has long been the standard of care for many lymphoma patients with relapsed follicular lymphoma (FL) and marginal zone lymphoma (MZL). Researchers on
Read More >
At the 2018 ASH Annual Meeting, Catherine Diefenbach, MD (New York University) – a past recipient of LRF’s Clinical Investigator Career Development Award – presented
Read More >Updated results from the JULIET trial, testing tisagenlecleucel (Kymriah) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), revealed encouraging long term results.
Read More >
As novel treatments have increased survival rates and changed treatment paradigms for lymphoma, the need to better understand the side effects of these new treatments
Read More >
In conjunction with the Mantle Cell Lymphoma Scientific Workshop, the Lymphoma Research Foundation announced two MCL Therapeutic Studies Grants, awarded to Sandeep Dave, MD,
Read More >
The Lymphoma Research Foundation (LRF) is pleased to announce that scientific proceedings and priorities from LRF’s Adherence in Oral Therapies Scientific Meeting has been published
Read More >
Lymphoma Research Foundation Publishes White Paper to Outline Key Issues Discussed During Second Oral Therapies Workshop In October 2017, The Lymphoma Research Foundation (LRF) convened
Read More >
Oral medications are being increasingly used to treat patients with lymphoma and chronic lymphocytic leukemia (CLL). Five oral drugs have been approved over the past
Read More >
